

Remicade.com HCP

Wireframes

Version 1.35

Created by Team Chemistry



Notes

- 1. Main graphic for branding and messaging
- 2. Indication buttons, activate on rollover (see next screen)
- 3. Space for callouts; links in each callout lead to registration, additional content or downloads



[Login](#) | [Registration](#) | [Patient Website](#)

Search Search

[Print](#) | [e-mail a Colleague](#)

REMICADE – making an impact across indications and across lives

1

- Over 1.2 million patients treated across all uses*
- With over 16 years of clinical trial experience and 5.7 million patient years since first exposure, REMICADE® is trusted worldwide†

Choose an indication

2 Rheumatoid Arthritis	Psoriatic Arthritis	Ankylosing Spondylitis	Crohn's Disease	Ulcerative Colitis	Pediatric Crohn's Disease	Plaque Psoriasis
---------------------------	---------------------	------------------------	-----------------	--------------------	---------------------------	------------------

3
Risk Evaluation and Mitigation Strategy (REMS) for REMICADE®
For Important Safety Information regarding serious infections, including tuberculosis and fungal infections, visit [here](#).

Receive the Latest News and Information
Register *now* to receive updates about REMICADE®.

MEDVERSATION
A resource to support informed medical conversations between you and your patients about certain immune-mediated inflammatory diseases and potential therapeutic options. [Learn more](#)

Get the Doctor Discussion Guides
The Doctor Discussion Guide is a useful tool for your patients. Click [here](#) to download.

NOTE: The copy contained herein is for positioning and illustrative purposes only. For approved site copy please see the manuscript.

IMPORTANT SAFETY INFORMATION

Important Safety Information | Medication Guide | Prescribing Information | Privacy Policy | Legal Notice
Site Map | About COBI | Contact Us | Unsubscribe | Infusion Overview

2010 © Centocor Ortho Biotech, Inc. This site is published by Centocor Ortho Biotech, Inc. which is solely responsible for its contents. It is intended for residents from the United States.





Notes

- 1. If user rolls over indication, space above fills with indication support copy.
- 2. Indication summary with link On rollover brief blurb appears in space
- 3. Learn more link takes user to indication landing page



[Login](#) | [Registration](#) | [Patient Website](#)

[Print](#) | [e-mail a Colleague](#)

2 Rheumatoid Arthritis
 REMICADE®, in combination with methotrexate, is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis.

3 Learn More >

Choose an indication

1 Rheumatoid Arthritis	Psoriatic Arthritis	Ankylosing Spondylitis	Crohn's Disease	Ulcerative Colitis	Pediatric Crohn's Disease	Plaque Psoriasis
-------------------------------	----------------------------	-------------------------------	------------------------	---------------------------	----------------------------------	-------------------------

Risk Evaluation and Mitigation Strategy (REMS) for REMICADE®
 For Important Safety Information regarding serious infections, including tuberculosis and fungal infections, visit [here](#).

MEDVERSATION
 A resource to support informed medical conversations between you and your patients about certain immune-mediated inflammatory diseases and potential therapeutic options. [Learn more](#)

Receive the Latest News and Information
[Register now](#) to receive updates about REMICADE®.

Get the Doctor Discussion Guides
 The Doctor Discussion Guide is a useful tool for your patients. Click [here](#) to download.

IMPORTANT SAFETY INFORMATION

Important Safety Information | Medication Guide | Prescribing Information | Privacy Policy | Legal Notice
 Site Map | About COBI | Contact Us | Unsubscribe | Infusion Overview

2010 © Centocor Ortho Biotech, Inc. This site is published by Centocor Ortho Biotech, Inc. which is solely responsible for its contents. It is intended for residents from the United States.



NOTE: The copy contained herein is for positioning and illustrative purposes only. For approved site copy please see the manuscript.



Notes

1. Callouts appear in left and right columns

[Login](#) | [Registration](#) | [Patient Website](#)

[Print](#) | [e-mail a Colleague](#)

Rheumatoid Arthritis	REMICADE Efficacy	Case Studies	Safety & Administration
----------------------	--------------------------	--------------	-------------------------

Risk Evaluation and Mitigation Strategy (REMS) for REMICADE®
For Important Safety Information regarding serious infections, including tuberculosis and fungal infections. **VISIT HERE**

MEDVERSATION
A resource to support informed medical conversations between you and your patients about certain immune-mediated inflammatory diseases and potential therapeutic options. **LEARN MORE**



Rheumatoid Arthritis Overview

REMICADE®, in combination with methotrexate, is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis.

REMICADE® has demonstrated efficacy across a range of clinical markers, in both early (?3 years) and established RA, as shown in the ASPIRE and ATTRACT clinical trials. In early RA, results were visible in some patients after just 1 infusion, and the majority of patients achieved clinical response through 1 year. The safety and efficacy of REMICADE® at the recommended dose was investigated in the START trial, as well as in those patients who required a dose escalation.

The recommended dose of REMICADE® is 3 mg/kg given as an intravenous induction regimen at 0, 2, and 6 weeks followed by a maintenance regimen of 3 mg/kg every 8 weeks thereafter for the treatment of moderately to severely active rheumatoid arthritis. REMICADE® should be given in combination with methotrexate. For patients who have an incomplete response, consideration may be given to adjusting the dose up to 10 mg/kg or treating as often as every 4 weeks, bearing in mind that risk of serious infections is increased at higher doses.

▼ Choose Another Indication

Get the Doctor Discussion Guides
The Doctor Discussion Guide is a useful tool for your patients. **DOWNLOAD**

Receive the Latest News and Information
Register *now* to receive updates about REMICADE®. **REGISTER**

[Important Safety Information](#) | [Medication Guide](#) | [Prescribing Information](#) | [Privacy Policy](#) | [Legal Notice](#)
[Site Map](#) | [About COBI](#) | [Contact Us](#) | [Unsubscribe](#) | [Infusion Overview](#)

IMPORTANT SAFETY INFORMATION
 Lorem ipsum dolor sit amet, consectetur adipiscing elit. Proin porta nunc sit amet nibh. Curabitur et ligula ac sapien gravida egestas. Suspendisse volutpat ipsum sagittis ligula. Duis lacinia neque ut justo. Morbi diam. Fusce est felis, pharetra ac, imperdiet quis, posuere eu, est. Aenean molestie, ipsum ut consectetur blandit, est eros pellentesque justo, a gravida tellus quam eu turpis.

 Centocor Ortho Biotech Inc.

2010 © Centocor Ortho Biotech, Inc. This site is published by Centocor Ortho Biotech, Inc. which is solely responsible for its contents. It is intended for residents from the United States.

NOTE: The copy contained herein is for positioning and illustrative purposes only. For approved site copy please see the manuscript.



Notes

- 1. Active sub-Section is highlighted in nav
- 2. Where additional content resides under subnav, vertical dropdowns display the next level options



[Login](#) | [Registration](#) | [Patient Website](#)

[Print](#) | [e-mail a Colleague](#)

Rheumatoid Arthritis

REMICADE Efficacy

Case Studies

Safety & Administration

Risk Evaluation and Mitigation Strategy (REMS) for REMICADE®

For Important Safety Information regarding serious infections, including tuberculosis and fungal infections, visit here.
[VISIT NOW](#)

MEDVERSATION

A resource to support informed medical conversations between you and your patients about certain immune-mediated inflammatory diseases and potential therapeutic options.
[LEARN MORE](#)

REMICADE® ASPIRE

In moderate to severe rheumatoid arthritis (RA) treatment...

SOME PATIENTS ACHIEVED ACR 20 RESPONSE AT 54 WEEKS^{1,2†}

At Week 2, significantly more patients treated with REMICADE® 3 mg/kg + methotrexate (MTX) (n=343) and REMICADE® 6 mg/kg + MTX (n=350) vs MTX alone (n=267) achieved ACR 20 response.¹

Proportion of patients who achieved ACR 20 response at Week 2¹

Treatment Group	44.9%	P<0.001
REMICADE® 3 mg/kg	44.9%	P<0.001
REMICADE® 6 mg/kg	45.4%	P<0.001
MTX alone	12.7%	

At Week 54, a greater proportion of patients treated with REMICADE® 3 mg/kg + MTX and REMICADE® 6 mg/kg + MTX achieved significant reduction in signs and symptoms from baseline, compared with methotrexate (MTX) alone, as shown by the primary endpoint.²

Proportion of patients who achieved ACR response at Week 54²

	ACR 20	ACR 50	ACR 70
REMICADE® 3 mg/kg	62% (P<0.05)	46% (P≤0.001)	33% (P<0.01)
REMICADE® 6 mg/kg	66% (P≤0.001)	50% (P≤0.001)	37% (P≤0.001)
MTX alone	54%	32%	21%

The significant reduction in RA signs and symptoms with both doses of REMICADE® + MTX, as measured by ACR response, was also consistent across a number of individual response variables for rapid, visible improvement.^{1†}

Improvement from baseline in ACR criteria at Week 2 and Week 54^{1†}
(median values presented)

▼ Choose Another Indication

Receive the Latest News and Information

Register *now* to receive updates about REMICADE®.
[REGISTER NOW](#)

Medication Guide for REMICADE®

Read the Medication Guide for REMICADE®, share it with your patients, and encourage discussion.
[DOWNLOAD HERE](#)

NOTE: The copy contained herein is for positioning and illustrative purposes only. For approved site copy please see the manuscript.

Notes

1. User has selected Aspire and menu has collapse back to initial state



2. Tabbed heading for section to navigate between study topic

breakdown. Tabs are indicated highlighted or dimmed to reflect on and off states.

NOTE: The copy contained herein is for positioning and illustrative purposes only. For approved site copy please see the manuscript.

Rheumatoid Arthritis | **1** REMICADE Efficacy | Case Studies | Safety & Administration

What is ASPIRE*?
 ASPIRE (Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset)

- A placebo-controlled study of 1004 methotrexate (MTX)-naive patients with moderately to severely active early rheumatoid arthritis (RA) (≤ 3 years).¹

ACR Response | Structural Damage | Physical Function

2 *In moderate to severely Rheumatoid Arthritis (RA) treatment..*
How quickly can you expect a response?

REMICADE® -- Too Important to Ignore

In Patients with early RA (≤ 3 years) ^{1,2*}

Some patients responded as early as 2 weeks, and a majority demonstrated response at 54 weeks^{1,2†}
 At Week 2, significantly more patients treated with REMICADE® 3 mg/kg + MTX (n=343) and REMICADE® 6 mg/kg + MTX (n=350) vs MTX alone (n=267) achieved ACR 20 response.¹

Proportion of patients who achieved ACR 20 response at Week 2¹

Treatment Group	ACR 20	P-value
REMICADE® 3 mg/kg	44.9%	$P < 0.001$
REMICADE® 6 mg/kg	45.4%	$P < 0.001$
MTX alone	12.7%	

At Week 54, a greater proportion of patients treated with REMICADE® 3 mg/kg + MTX and REMICADE® 6 mg/kg + MTX achieved significant reduction in signs and symptoms from baseline, compared with methotrexate (MTX) alone, as shown by the primary endpoint.²

Proportion of patients who achieved ACR response at Week 54²

Treatment Group	ACR 20	ACR 50	ACR 70
REMICADE® 3 mg/kg	62% ($P < 0.05$)	46% ($P \leq 0.001$)	33% ($P < 0.01$)
REMICADE® 6 mg/kg	66% ($P \leq 0.001$)	50% ($P \leq 0.001$)	37% ($P \leq 0.001$)
MTX alone	54%	32%	21%

Risk Evaluation and Mitigation Strategy (REMS) for REMICADE®
 For Important Safety Information regarding serious infections, including tuberculosis and fungal infections, [VISIT HERE](#)

MEDVERSATION
 A resource to support informed medical conversations between you and your patients about certain immune-mediated inflammatory diseases and potential therapeutic options. [LEARN MORE](#)

Receive the Latest News and Information
 Register *now* to receive updates about REMICADE®. [REGISTER NOW](#)

Medication Guide for REMICADE®
 Read the Medication Guide for REMICADE®, share it with your patients, and encourage discussion. [DOWNLOAD HERE](#)

Choose Another Indication



Notes

1. Example of Case Studies as represented with tab subnavigation; same functionality at Efficacy section.

The wireframe shows the Remicade.com HCP interface. At the top right, there are links for [Login](#), [Registration](#), and [Patient Website](#). Below these is a search bar with a [Search](#) button and a [Print](#) / [e-mail a Colleague](#) link. The main navigation bar includes [Rheumatoid Arthritis](#), [REMICADE Efficacy](#), [Case Studies](#) (highlighted with a black border), and [Safety & Administration](#). Under the [Case Studies](#) tab, there are three sub-tabs: [Case Study 1](#) (with a blue circle containing the number 1), [Case Study 2](#), and [Case Study 3](#). The [Case Study 1](#) content area displays the title **Case Study 1 – REMICADE: Rapid Response to Signs and Symptoms¹**, followed by patient details: "Female, 40 years of age, moderate to severe rheumatoid arthritis (RA)". A bulleted list includes: "Diagnosed: mid 30s", "Weight: 125 lbs (<65 kg)", "Current medication: prednisone", "CRP: (≥2 mg/dL)", "≥10 swollen and ≥12 tender joints", and "Erosions observed on X-ray". Below the list, it states: "In some patients, ACR responses were achieved as early as 2 weeks, including substantial reduction of CRP.¹". To the left of the main content is a sidebar with two sections: "Risk Evaluation and Mitigation Strategy (REMS) for REMICADE®" with a [VISIT HERE](#) link, and "MEDVERSATION" with a [LEARN MORE](#) link. To the right is another sidebar with "Receive the Latest News and Information" (with a [REGISTER NOW](#) link) and "Medication Guide for REMICADE®" (with a [DOWNLOAD HERE](#) link). At the bottom of the wireframe, there is a footer with links for [Important Safety Information](#), [Medication Guide](#), [Prescribing Information](#), [Privacy Policy](#), [Legal Notice](#), [Site Map](#), [About COBI](#), [Contact Us](#), [Unsubscribe](#), and [Infusion Overview](#). The Centocor Ortho Biotech Inc. logo is in the bottom left, and copyright information is in the bottom right.

NOTE: The copy contained herein is for positioning and illustrative purposes only. For approved site copy please see the manuscript.



Notes

1. Disclaimer overlay for links outside of the site. User has option to continue or cancel. Closing window at box in upper right will do the same as cancel.

The screenshot shows the Remicade.com Professional Support page. At the top right, there are links for Login, Registration, and Patient Website, along with a search bar and a 'Search' button. Below this is a navigation bar with 'Professional Support', 'Registration', and 'Specialist Locator Enrollment' tabs. The main content area is titled 'Information for Your Patients' and includes a dropdown menu for 'Choose Another Indication'. The text on the page discusses downloading the REMICADE® Doctor Discussion Guide and lists several services available through AccessOne®, such as specialty pharmacy identification, care coordinator assignment, reimbursement support, real-time tracking, and medication shipment history. A disclaimer overlay is present, stating that clicking on external links will take users to a website where the site's privacy policy does not apply. The overlay includes 'Cancel' and 'Continue' buttons. At the bottom of the page, there is a footer with 'Important Safety Information' and 'Centocor Ortho Biotech Inc.' logo.

NOTE: The copy contained herein is for positioning and illustrative purposes only. For approved site copy please see the manuscript.



Header links change depending if user is logged in or out.

Logout | My Profile

1 Login | 2 Registration | 3 Patient Website
4 Search Search
5 Print | e-mail a Colleague
6

Notes

1. Links to login screen; if user is logged in, link is then titled "Logout"
2. Links to Registration page; if user is logged in, link is titled "My Profile"
3. Links to patient website
4. Open text box and submit button takes user to search results
5. Creates printer-friendly version of current page
6. Takes user to e-mail a colleague form for current page
7. Important Safety Information, full ISI
- 8, Links to PDF of Medication Guide
9. Links to PDF of Prescribing Information
10. Links to Privacy Policy
11. Links to Legal Notice
12. Links to Site Map
13. Links to About COBI page
14. Links to Contact Us information
15. Links to unsubscribe popup; user must take action in popup to unsubscribe
16. Links to Infusion Overview

Rheumatoid Arthritis | **REMICADE Efficacy** | **Case Studies** | **Safety & Administration**

Risk Evaluation and Mitigation Strategy (REMS) for REMICADE®
For Important Safety Information regarding serious infections, including tuberculosis and fungal infections, **VISIT HERE**

MEDVERSATION
A resource to support informed medical conversations between you and your patients about certain immune-mediated inflammatory diseases and potential therapeutic options. **LEARN MORE**

Safety and Administration
The recommended dose of REMICADE® for the treatment of moderately to severely active rheumatoid arthritis is:

- 3 mg/kg given as an intravenous induction regimen at 0, 2, and 6 weeks followed by a maintenance regimen of 3 mg/kg every 8 weeks thereafter.¹
- REMICADE® should be given in combination with methotrexate.¹

For patients who have incomplete responses, consideration may be given to adjusting the dose up to 10 mg/kg or treating as often as every 4 weeks, bearing in mind that the risk of serious infections is increased at higher doses.¹

Choose Another Indication

Receive the Latest News and Information
Register *now* to receive updates about REMICADE®. **REGISTER NOW**

Medication Guide for REMICADE®
Read the Medication Guide for REMICADE®, share it with your patients, and encourage discussion. **DOWNLOAD HERE**

7 Important Safety Information | 8 Medication Guide | 9 Prescribing Information | 10 Privacy Policy | 11 Legal Notice
12 Site Map | 13 About COBI | 14 Contact Us | 15 Unsubscribe | 16 Infusion Overview

IMPORTANT SAFETY INFORMATION
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Proin porta nunc sit amet nibh. Curabitur et ligula ac sapien gravida. Vestibulum convallis. Sed euismod. Morbi diam. Fusce est felis, pharetra ac, imperdiet quis, posuere eu, est. Aenean molestie, ipsum ut consectetur blandit, est eros pellentesque justo, a gravida tellus quam eu turpis.

Centocor Ortho Biotech Inc.
2010 © Centocor Ortho Biotech, Inc. This site is published by Centocor Ortho Biotech, Inc. which is solely responsible for its contents. It is intended for residents from the United States.

NOTE: The copy contained herein is for positioning and illustrative purposes only. For approved site copy please see the manuscript.

Notes

How Error Messages are Marked up in this Document

- Within each wireframe of each page, error messages are presented in this Notes column to the left of the page illustration (see below)

Representative Contextual Error Message Display

Error messages in actual form should be displayed as illustrated to right:

- Underneath the invalid field or form element
- Error messages should be positioned as close as possible to the field where the error occurred
- In HTML text, red,

* Registrant contact type
Registration contact type is a required field

*Address of practice
Address of practice is a required field

Address 2

*City
City is a required field

*State
You must select a state

*ZIP
Please enter a valid ZIP code

Academic Degree

SLN#

Do you have in-office infusion capability?
 Yes No

I would like a REMICADE® sales representative to visit my office.

<p>Error Messages</p> <ol style="list-style-type: none"> 1. Registration contact type is a required field 2. Address of practice is a required field 3. City is a required field 4. You must select a state 5. Please enter a valid ZIP code 6. If user selects state, corresponding field, must be at least 6 numeric characters 7. Accepting terms of use is required <p>Additional</p>	<p>Thank you for logging in. C</p> <p>What is your specialty or area of practice?</p> <p> <input type="radio"/> Rheumatology <input type="radio"/> Gastroenterology <input type="radio"/> Dermatology <input checked="" type="radio"/> Internal Medicine, General or Family <input type="radio"/> Pediatrics <input type="radio"/> Other </p> <p>1 * Registrant contact type <input type="text" value="- sele"/></p> <p>2 *Address of practice <input type="text"/></p> <p>Address 2 <input type="text"/></p> <p>3 *City <input type="text"/></p> <p>4 *State <input type="text" value="- sele"/></p> <p>5 *ZIP <input type="text"/></p> <p>Academic Degree <input type="text" value="- sele"/></p> <p>6 SLN# <input type="text" value="- sele"/></p>
--	---

NOTE: The copy contained herein is for positioning and illustrative purposes only. For approved site copy please see the manuscript.



Notes

Error Messages

- 1. You must enter your name
- 2. A valid e-mail address is required
- 3. You must enter your colleague's name
- 4. A valid e-mail address is required



[Login](#) | [Registration](#) | [Patient Website](#)

[Print](#) | [e-mail a Colleague](#)

e-mail a Colleague



Do you know someone who would like to learn more about REMICADE (infliximab)?
Sending this Website to a colleague could help.

This form will send your colleague a link to the page you were just browsing.
The information entered on this page will not be used to send unsolicited e-mails and will not be sent to a third party.

By submitting an e-mail address, you are requesting that we contact on your behalf the person you specify here. Your name and contact information and your friend's contact information are required, but they will not be used other than to distribute the communication you request.

***Required Fields**

1

2

3

4

*Your name

*Your e-mail

*Your colleague's name

*Your colleagues e-mail

[Important Safety Information](#) | [Medication Guide](#) | [Prescribing Information](#) | [Privacy Policy](#) | [Legal Notice](#)
[Site Map](#) | [About COBI](#) | [Contact Us](#) | [Unsubscribe](#) | [Infusion Overview](#)

IMPORTANT SAFETY INFORMATION
 Lorem ipsum dolor sit amet, consectetur adipiscing elit. Proin porta nunc sit amet nibh. Curabitur et ligula ac sapien gravida egestas. Suspendisse volutpat ipsum sagittis ligula. Duis lacinia neque ut justo. Morbi diam. Fusce est felis, pharetra ac, imperdiet quis, posuere eu, est. Aenean molestie, ipsum ut consectetur blandit, est eros pellentesque justo, a gravida tellus quam eu turpis.



2010 © Centocor Ortho Biotech, Inc. This site is published by Centocor Ortho Biotech, Inc. which is solely responsible for its contents. It is intended for residents from the United States.

NOTE: The copy contained herein is for positioning and illustrative purposes only. For approved site copy please see the manuscript.



Notes

Error Messages

- 1. You must be at least 18 years of age to register
- 2. First name is a required field
- 3. Last name is a required field
- 4. A valid e-mail address is required
- 5. E-mail addresses do not match

Additional

- 6. Form will be presented with the same subnavigation the user originated from
- 7. Link to a login screen
- 8. Submit and validate data from form
- 9. Successful submission of form returns this message in same page

[Login](#) | [Registration](#) | [Patient Website](#)

[Print](#) | [e-mail a Colleague](#)

6	Rheumatoid Arthritis	REMICADE Efficacy	Case Studies	Safety & Administration
----------	----------------------	-------------------	--------------	-------------------------

Registration for Updates

Please provide the information requested below so that we can e-mail you a temporary password

7 [Already registered? Login here](#)

Your name, address, and other information that you provide will be used by Centocor Ortho Biotech Inc., and companies that work on our behalf, including vendors and other affiliates, to fulfill your request. If you would like to receive communications from REMICADE®, please confirm the following:

1 *Note: Must be 18 years of age or older to receive additional information.*
 I am at least 18 years of age.

2 *First Name

3 *Last Name

4 *e-mail

5 *Confirm e-mail

† We may contact you with information about REMICADE® and the indications REMICADE® is approved to treat. Centocor Ortho Biotech Inc. may also contact you with information and updates about other products or services that may interest you. Centocor Ortho Biotech Inc. will not share your information with anyone else, except as required by law.

9 **Thank you for beginning the registration process for REMICADE®.**

Please check your e-mail for your temporary password.

button below, you accept the terms of use collected on this form and agree to provide will be governed by our site's [Privacy Policy](#).

giving this information, you may ask us to remove you from our contact list by 877-MY REMICADE (877-XXX-XXXX) or by visiting www.REMICADE.com/

8

NOTE: The copy contained herein is for positioning and layout only. For approved site copy please see the manuscript.

Notes

Error Messages

1. You must be at least 18 years of age to register
2. First name is a required field
3. Last name is a required field
4. A valid e-mail address is required
5. E-mail addresses do not match

Additional

6. Form will not be presented with subnavigation as the user has not self-identified with any indication
7. Link to a login screen
8. Submit and validate data from form
9. Successful submission of form returns this message in same page

[Login](#) | [Registration](#) | [Patient Website](#)

[Print](#) | [e-mail a Colleague](#)

6 HOME

Registration for Updates

Please provide the information requested below so that we can e-mail you a temporary password

7 **Already registered?**
[Login here](#)

Your name, address, and other information that you provide will be used by Centocor Ortho Biotech Inc., and companies that work on our behalf, including vendors and other affiliates, to fulfill your request. If you would like to receive communications from REMICADE®, please confirm the following:

1 *Note: Must be 18 years of age or older to receive additional information.*
 I am at least 18 years of age.

2 *First Name

3 *Last Name

4 *e-mail

5 *Confirm e-mail

† We may contact you with information about REMICADE® and the indications REMICADE® is approved to treat. Centocor Ortho Biotech Inc. may also contact you with information and updates about other products or services that may interest you. Centocor Ortho Biotech Inc. will not share your information with anyone else, except as required by law.

By clicking the button below, you accept the terms of use collected on this form and agree that your information and any data you provide will be governed by our site's [Privacy Policy](#).

If you are already registered, you may ask us to remove you from our contact list by calling 1-877-MY REMICADE (877-XXX-XXXX) or by visiting www.REMICADE.com/

8

9 **Thank you for beginning the registration process for REMICADE®.**

Please check your e-mail for your temporary password.

NOTE: The copy contained herein is for positioning a placeholder only. For approved site copy please see the manuscript.

Notes

1. E-mail addresses are representative, but subject and message are as per manuscript

1 TO: joansmith@domain.com

FROM: Updates from Centocor Ortho Biotech Inc.

SUBJECT: Your Temporary Password From REMICADE.com

MESSAGE:

We appreciate your interest in REMICADE®

Your username is your e-mail address: joansmith@domain.com.
Click the link below to finish creating your REMICADE® profile.

www.remicade.com/hcp/myprofile [Link to: 8.1]

Your password is: <XXXXXXXX>
Thank you.

Please use this information to sign in and create your REMICADE® profile.
Thank you.

NOTE: The copy contained herein is for positioning and illustrative purposes only. For approved site copy please see the manuscript.

Notes

1. E-mail addresses are representative, but subject and message are as per manuscript

1

TO: joansmith@domain.com

FROM: Updates from Centocor Ortho Biotech Inc.

SUBJECT: Resetting Your Password: Temporary Password From REMICADE.com

MESSAGE:

We appreciate your interest in REMICADE®

Your username is your e-mail address: joansmith@domain.com.
Click the link below to reset your password.

www.remicade.com/hcp/myprofile [Link to: 8.1]

Your password is: <XXXXXXXX>
Thank you.

Please use this information to sign in and reset your password.

Thank you.

NOTE: The copy contained herein is for positioning and illustrative purposes only. For approved site copy please see the manuscript.



Notes

Error Messages

1. A valid Email address is required (where e-mail address not formatted correctly)

2. The Email address or Password you entered is incorrect.

Additional

3. Email address is the username

4. Forgot password link takes them to another page to retrieve their password.

5. Login button - upon successful submission of data takes the user to their "My Profile" page

NOTE: The copy contained herein is for positioning and illustrative purposes only. For approved site copy please see the manuscript.

[Login](#) | [Registration](#) | [Patient Website](#)

Search

[Print](#) | [e-mail a Colleague](#)

HOME

Login for Health Care Professionals

Please enter your email and password below to Login

1 2 3 4 5

Email address

Password

[Forgot Password](#)

[Important Safety Information](#) | [Medication Guide](#) | [Prescribing Information](#) | [Privacy Policy](#) | [Legal Notice](#)
[Site Map](#) | [About COBI](#) | [Contact Us](#) | [Unsubscribe](#) | [Infusion Overview](#)

IMPORTANT SAFETY INFORMATION
 Lorem ipsum dolor sit amet, consectetur adipiscing elit. Proin porta nunc sit amet nibh. Curabitur et ligula ac sapien gravida egestas. Suspendisse volutpat ipsum sagittis ligula. Duis lacinia neque ut justo. Morbi diam. Fusce est felis, pharetra ac, imperdiet quis, posuere eu, est. Aenean molestie, ipsum ut consectetur blandit, est eros pellentesque justo, a gravida tellus quam eu turpis.

Centocor Ortho Biotech Inc.

2010 © Centocor Ortho Biotech, Inc. This site is published by Centocor Ortho Biotech, Inc. which is solely responsible for its contents. It is intended for residents from the United States.



Notes

Error Messages

- 1. A valid e-mail address is required
- 2. Temporary password is incorrect
- 3. Password must be at least 6 characters including a number
- 4. Passwords do not match

Additional

- 5. Submit and validate data from form
- 6. Successful submission of form takes user to the user's profile page

NOTE: The copy contained herein is for positioning and illustrative purposes only. For approved site copy please see the manuscript.



[Login](#) | [Registration](#) | [Patient Website](#)

[Print](#) | [e-mail a Colleague](#)

Rheumatoid Arthritis	REMICADE Efficacy	Case Studies	Safety & Administration
----------------------	-------------------	--------------	-------------------------

Create Your New Password

Please enter your username (e-mail address) and temporary password to sign in

1 *Email address

2 *Temporary Password

3 *New Password

4 *Confirm New Password

5

Notes


Error Messages

1. The e-mail address you entered is not in our records (where e-mail address is not in current database records)
2. A valid e-mail address is required (where e-mail address not formatted correctly)

Additional

3. Submit and validate data from form
4. Successful submission of form results in confirmation message posted in same page

NOTE: The copy contained herein is for positioning and illustrative purposes only. For approved site copy please see the manuscript.



[Login](#) | [Registration](#) | [Patient Website](#)

Search Search

[Print](#) | [e-mail a Colleague](#)

Rheumatoid Arthritis	REMICADE Efficacy	Case Studies	Safety & Administration
----------------------	-------------------	--------------	-------------------------

Forgot Password

Please enter your E-mail address and click "Reset Password"
Instructions for recovering your password will be sent to the e-mail address that you provide below. Once you retrieve your password, please return to the log in page.

*E-mail address

Please check your e-mail for your new password



Notes

Error Messages

- 1. A valid e-mail address is required
- 2. Temporary password is incorrect
- 3. Password must be at least 6 characters including a number
- 4. Passwords do not match

Additional

- 5. Submit and validate data from form
- 6. Successful submission of form takes user to the user's profile page

NOTE: The copy contained herein is for positioning and illustrative purposes only. For approved site copy please see the manuscript.

Notes

Error Messages

1. The e-mail address you entered is not in our records (where e-mail address is not in current database records)


2. A valid e-mail address is required (where e-mail address not formatted correctly)

Additional

3. Submit and validate data from form

4. Successful submission of form results in confirmation message posted in same page

5. As user has arrived at this page via the home page, there will be no subnavigation.



NOTE: The copy contained herein is for positioning and illustrative purposes only. For approved site copy please see the manuscript.



Notes

A. This represents form use case if user is Internal Medicine, General or Family Practice. For this instance, no other questions are asked (medications prescribed, in-office infusion, etc.)

Error Messages

- 1. Registration contact type is a required field
2. Address of practice is a required field
3. City is a required field
4. You must select a state
5. Please enter a valid 5 or 9 digit ZIP code
6. Combo box will be used for this field specifically
7. If user selects state, corresponding field must contain numeric characters
8. Accepting terms of use is required

Additional

- 9. Submit and validate data from form
10. Successful submission of form results in confirmation message posted on same page

NOTE: The copy contained herein is for positioning and illustrative purposes only. For approved site copy please see the manuscript.

Wireframe of the 'Create Your REMICADE® Profile' form. Includes Remicade logo, navigation links (Logout, My Profile, Patient Website), search bar, and a list of specialties (Rheumatology, Gastroenterology, Dermatology, Internal Medicine, Pediatrics, Other). Form fields include: Registrant contact type, Address of practice, Address 2, City, State, ZIP, Academic Degree, and SLN#. A 'CREATE PROFILE' button is present, along with a checkbox for 'I accept the terms of use of the information on this form'. Footer includes Centocor Ortho Biotech Inc. logo and important safety information.



Notes

A. This represents form use case if the user has self-identified themselves via a gastric condition (CD, UC), By default Gastroenterologist is selected.

Error Messages

- 1. Registration contact type is a required field
- 2. Address of practice is a required field
- 3. City is a required field
- 4. You must select a state
- 5. Please enter a valid 5 or 9 digit ZIP code
- 6. Combo box will be used for this field specifically
- 7. If user selects state, corresponding field must contain numeric characters
- 8. User can select one radio button per row

Form continues on next page

NOTE: The copy contained herein is for positioning and illustrative purposes only. For approved site copy please see the manuscript.

[Logout](#) | [My Profile](#) | [Patient Website](#)

[Print](#) | [e-mail a Colleague](#)

Rheumatoid Arthritis	REMICADE Efficacy	Case Studies	Safety & Administration
----------------------	-------------------	--------------	-------------------------

Thank you for logging in. Create Your REMICADE® Profile

What is your specialty or area of practice?

Rheumatology
 Gastroenterology
 Dermatology
 Internal Medicine, General or Family Practice
 Pediatrics
 Other

* Required fields

1 *Registrant contact type

2 *Address of practice

Suite/floor

3 *City

4 *State

5 *ZIP

6 Academic Degree

7 SLN#

How often do you prescribe a biologic for the following conditions?

	Frequently	Sometimes	Rarely	Never
8 Crohn's Disease	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Ulcerative Colitis	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Continued on next page

Notes**Error Messages**

1. Checkbox, not required
2. Accepting terms of use is required

Additional

3. Submit and validate data from form
4. Successful submission of form results in confirmation message posting on same page

Continued from previous page

Which biologic do you prescribe most often?

- Cimzia® (certolizumab pegol)
 Humira® (adalimumab)
 REMICADE® (infliximab)

Do you have in-office infusion capability?

- Yes No

I would like a REMICADE® sales representative visit my office.

I accept the terms of use of the information on this form

SUBMIT

Thank you for creating your profile.

NOTE: The copy contained herein is for positioning and illustrative purposes only. For approved site copy please see the manuscript.

IMPORTANT SAFETY INFORMATION

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Proin porta nunc sit amet nibh. Curabitur et ligula ac sapien gravida egestas. Suspendisse volutpat ipsum sagittis ligula. Duis lacinia neque ut justo. Morbi diam. Fusce est felis, pharetra ac, imperdiet quis, posuere eu, est. Aenean molestie, ipsum ut consectetur blandit, est eros pellentesque justo, a gravida tellus quam eu turpis.



[Important Safety Information](#) | [Medication Guide](#) | [Prescribing Information](#) | [Privacy Policy](#) | [Legal Notice](#)
[Site Map](#) | [About COBI](#) | [Contact Us](#) | [Unsubscribe](#) | [Infusion Overview](#)

2010 © Centocor Ortho Biotech, Inc. This site is published by Centocor Ortho Biotech, Inc. which is solely responsible for its contents. It is intended for residents from the United States.

Notes

A. This represents form use case if the user has self-identified themselves via a rheumatic condition (RA, AS, PsA). By default Rheumatologist is selected.

Error Messages

1. Registration contact type is a required field
2. Address of practice is a required field
3. City is a required field
4. You must select a state
5. Please enter a valid 5 or 9 digit ZIP code
6. Combo box will be used for this field specifically
7. If user selects state, corresponding field must contain numeric characters
8. User can select one radio button per row

Form continues on next page

NOTE: The copy contained herein is for positioning and illustrative purposes only. For approved site copy please see the manuscript.

[Logout](#) | [My Profile](#) | [Patient Website](#)

[Print](#) | [e-mail a Colleague](#)

Rheumatoid Arthritis	REMICADE Efficacy	Case Studies	Safety & Administration
----------------------	-------------------	--------------	-------------------------

Thank you for signing in. Create Your REMICADE® Profile

What is your specialty or area of practice?

Rheumatology
 Gastroenterology
 Dermatology
 Internal Medicine, General or Family Practice
 Pediatrics
 Other

* Required fields

1 # Registrant contact type

2 *Address of practice

Suite/floor

3 *City

4 *State

5 *ZIP

6 Academic Degree

7 SLN#

How often do you prescribe a biologic for the following conditions?

	Frequently	Sometimes	Rarely	Never
7 Ankylosing Spondylitis	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Rheumatoid Arthritis	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Plaque Psoriasis	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Psoriatic Arthritis	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Continued on next page

Notes**Error Messages**

1. Checkbox, not required
2. **Accepting terms of use is required**

Additional

3. Submit and validate data from form
4. Successful submission of form results in confirmation message posting on same page

Continued from previous page

Which biologic do you prescribe most often?

- Cimzia® (certolizumab pegol)
- Enbrel® (etanercept)
- Humira® (adalimumab)
- Orencia® (abatacept)
- REMICADE® (infliximab)
- Ritaxan® (rituximab)
- Simponi® (golimumab)

Do you have in-office infusion capability?

- Yes
- No

1 I would like a REMICADE® sales representative visit my office.

2 I accept the terms of use of the information on this form

3 **SUBMIT**

4

Thank you for creating your profile.

NOTE: The copy contained herein is for positioning and illustrative purposes only. For approved site copy please see the manuscript.

IMPORTANT SAFETY INFORMATION

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Proin porta nunc sit amet nibh. Curabitur et ligula ac sapien gravida egestas. Suspendisse volutpat ipsum sagittis ligula. Duis lacinia neque ut justo. Morbi diam. Fusce est felis, pharetra ac, imperdiet quis, posuere eu, est. Aenean molestie, ipsum ut consectetur blandit, est eros pellentesque justo, a gravida tellus quam eu turpis.



[Important Safety Information](#) | [Medication Guide](#) | [Prescribing Information](#) | [Privacy Policy](#) | [Legal Notice](#)
[Site Map](#) | [About COBI](#) | [Contact Us](#) | [Unsubscribe](#) | [Infusion Overview](#)

2010 © Centocor Ortho Biotech, Inc. This site is published by Centocor Ortho Biotech, Inc. which is solely responsible for its contents. It is intended for residents from the United States.



Notes

A. This represents form use case if the user has self-identified themselves via a PCD.

Error Messages

- 1. Registration contact type is a required field
- 2. Address of practice is a required field
- 3. City is a required field
- 4. You must select a state
- 5. Please enter a valid 5 or 9 digit ZIP code
- 6. Combo box will be used for this field specifically
- 7. If user selects state, corresponding field must contain numeric characters
- 8. User can select one radio button per row

Form continues on next page

NOTE: The copy contained herein is for positioning and illustrative purposes only. For approved site copy please see the manuscript.

[Logout](#) | [My Profile](#) | [Patient Website](#)

[Print](#) | [e-mail a Colleague](#)

Rheumatoid Arthritis	REMICADE Efficacy	Case Studies	Safety & Administration
----------------------	-------------------	--------------	-------------------------

Thank you for signing in. Create Your REMICADE Profile

What is your specialty or area of practice?

Rheumatology
 Gastroenterology
 Dermatology
 Internal Medicine, General or Family Practice
 Pediatrics
 Other

* Required fields

1

Registrant contact type

- select -

2

*Address of practice

Suite/floor

3

*City

4

*State

- select state -

5

*ZIP

6

Academic Degree

- select degree -

7

SLN#

- select state -

How often do you prescribe a biologic for the following conditions?

	Frequently	Sometimes	Rarely	Never
8				
Crohn's Disease	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Ulcerative Colitis	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Continued on next page

Notes**Error Messages**

1. Checkbox, not required
2. Accepting terms of use is required

Additional

3. Submit and validate data from form
4. Successful submission of form results in confirmation message posting on same page

Continued from
previous page

Do you prescribe REMICADE for Pediatric Crohn's Disease?

Yes No

Do you have in-office infusion capability?

Yes No

1 I would like a REMICADE® sales representative visit my office.

2 I accept the terms of use of
the information on this form

3
SUBMIT

4
Thank you for creating your profile.

NOTE: The copy contained herein is for positioning and illustrative purposes only. For approved site copy please see the manuscript.

IMPORTANT SAFETY INFORMATION

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Proin porta nunc sit amet nibh. Curabitur et ligula ac sapien gravida egestas. Suspendisse volutpat ipsum sagittis ligula. Duis lacinia neque ut justo. Morbi diam. Fusce est felis, pharetra ac, imperdiet quis, posuere eu, est. Aenean molestie, ipsum ut consectetur blandit, est eros pellentesque justo, a gravida tellus quam eu turpis.



[Important Safety Information](#) | [Medication Guide](#) | [Prescribing Information](#) | [Privacy Policy](#) | [Legal Notice](#)
[Site Map](#) | [About COBI](#) | [Contact Us](#) | [Unsubscribe](#) | [Infusion Overview](#)

2010 © Centocor Ortho Biotech, Inc. This site is published by Centocor Ortho Biotech, Inc. which is solely responsible for its contents. It is intended for residents from the United States.



Notes

A. This represents form use case if the user has self-identified themselves via a Plaque Psoriasis.

Error Messages

- 1. Registration contact type is a required field
- 2. Address of practice is a required field
- 3. City is a required field
- 4. You must select a state
- 5. Please enter a valid 5 or 9 digit ZIP code
- 6. Combo box will be used for this field specifically
- 7. If user selects state, corresponding field must contain numeric characters
- 8. One radio button selection per row permitted

Form continues on next page

NOTE: The copy contained herein is for positioning and illustrative purposes only. For approved site copy please see the manuscript.

[Logout](#) | [My Profile](#) | [Patient Website](#)

[Print](#) | [e-mail a Colleague](#)

Rheumatoid Arthritis	REMICADE Efficacy	Case Studies	Safety & Administration
----------------------	-------------------	--------------	-------------------------

Thank you for signing in. Create Your REMICADE Profile

What is your specialty or area of practice?

Rheumatology
 Gastroenterology
 Dermatology
 Internal Medicine, General or Family Practice
 Pediatrics
 Other

* Required fields

1 # Registrant contact type

2 *Address of practice

Suite/floor

3 *City

4 *State

5 *ZIP

6 Academic Degree

7 SLN#

8 How often do you prescribe a biologic for the plaque psoriasis?

Frequently
 Sometimes
 Rarely
 Never

Continued on next page

Notes**Error Messages**

1. Checkbox, not required
2. Accepting terms of use is required

Additional

3. Submit and validate data from form
4. Successful submission of form results in confirmation message posting on same page

Continued from previous page

Which biologic do you prescribe most often?

- Enbrel® (etanercept)
 Humira® (adalimumab)
 REMICADE® (infliximab)
 Stelara® (ustekinumab)

Do you have in-office infusion capability?

- Yes No

1 I would like a REMICADE® sales representative visit my office.

2 I accept the terms of use of the information on this form

3

4 **Thank you for creating your profile.**

NOTE: The copy contained herein is for positioning and illustrative purposes only. For approved site copy please see the manuscript.

IMPORTANT SAFETY INFORMATION

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Proin porta nunc sit amet nibh. Curabitur et ligula ac sapien gravida egestas. Suspendisse volutpat ipsum sagittis ligula. Duis lacinia neque ut justo. Morbi diam. Fusce est felis, pharetra ac, imperdiet quis, posuere eu, est. Aenean molestie, ipsum ut consectetur blandit, est eros pellentesque justo, a gravida tellus quam eu turpis.



[Important Safety Information](#) | [Medication Guide](#) | [Prescribing Information](#) | [Privacy Policy](#) | [Legal Notice](#)
[Site Map](#) | [About COBI](#) | [Contact Us](#) | [Unsubscribe](#) | [Infusion Overview](#)

2010 © Centocor Ortho Biotech, Inc. This site is published by Centocor Ortho Biotech, Inc. which is solely responsible for its contents. It is intended for residents from the United States.

Notes

Error Messages

1. User accesses this page by clicking on Registration in the header and logging in or clicking on "My Profile" if they are already logged in.
2. Form is presented prepopulated with the values from the user's previous entries. All fields are editable and error messaging is the same as the "Create Profile" screens.
3. Upon successful completion of Profile, the user will be presented with a confirmation message.

3 **Thank you for updating your profile.**

NOTE: The copy contained herein is for positioning and illustrative purposes only. For approved site copy please see the manuscript.

Continued on next page



1 [Logout](#) | [My Profile](#) | [Patient Website](#)

Search

[Print](#) | [e-mail a Colleague](#)

Rheumatoid Arthritis

REMICADE Efficacy

Case Studies

Safety & Administration

Edit Your REMICADE® Profile

2 What is your specialty or area of practice?

- Rheumatology
- Gastroenterology
- Dermatology
- Internal Medicine, General or Family Practice
- Pediatrics
- Other

* Required fields

Registrant contact type

*Address of practice

Suite/floor

*City

*State

*ZIP

Academic Degree

SLN#

How often do you prescribe a biologic for the following conditions?

	Frequently	Sometimes	Rarely	Never
Ankylosing Spondylitis	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>
Rheumatoid Arthritis	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Plaque Psoriasis	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Psoriatic Arthritis	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>

**Notes****1. Search Term**

Search term repeats in the search results title.

2. Pagination and results navigation

If the search term returns more results that can be displayed on one page, pagination and navigation will appear above and below the search results

NOTE: The copy contained herein is for positioning and illustrative purposes only. For approved site copy please see the manuscript.

**Search results for: {search term}**1 2 3 4 5 [next >](#) [last »](#)**1. Lorem ipsum dolor sit amet, consectetur adipiscing elit.**

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque viverra viverra risus auctor faucibus. In leo quam, porttitor vel blandit a, porta quis lectus. Sed in semper metus. Pellentesque pellentesque ornare nunc.

2. Nunc condimentum mauris in eros vestibulum euismod.

Pellentesque eget ligula quis est malesuada pulvinar ut id mauris. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque viverra viverra risus auctor faucibus.

3. Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque viverra viverra risus auctor faucibus. In leo quam, porttitor vel blandit a, porta quis lectus. Sed in semper metus. Pellentesque pellentesque ornare nunc.

4. Nunc condimentum mauris in eros vestibulum euismod.

Pellentesque eget ligula quis est malesuada pulvinar ut id mauris. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque viverra viverra risus auctor faucibus.

5. Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque viverra viverra risus auctor faucibus. In leo quam, porttitor vel blandit a, porta quis lectus. Sed in semper metus. Pellentesque pellentesque ornare nunc.



Notes



[Login](#) | [Registration](#) | [Patient Website](#)

Search

[Print](#) | [e-mail a Colleague](#)

Unsubscribe from Remicade.com

I do not wish to receive further communications about the following products or services from Centocor Ortho Biotech Inc., or from companies that work with Centocor Ortho Biotech Inc., including other affiliates and parent companies, to support Centocor Ortho Biotech Inc.'s business:

e-mail

Password

NOTE: The copy contained herein is for positioning and illustrative purposes only. For approved site copy please see the manuscript.

[Important Safety Information](#) | [Medication Guide](#) | [Prescribing Information](#) | [Privacy Policy](#) | [Legal Notice](#)
[Site Map](#) | [About COBI](#) | [Contact Us](#) | [Unsubscribe](#) | [Infusion Overview](#)

IMPORTANT SAFETY INFORMATION

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Proin porta nunc sit amet nibh. Curabitur et ligula ac sapien gravida egestas. Suspendisse volutpat ipsum sagittis ligula. Duis lacinia neque ut justo. Morbi diam. Fusce est felis, pharetra ac, imperdiet quis, posuere eu, est. Aenean molestie, ipsum ut consectetur blandit, est eros pellentesque justo, a gravida tellus quam eu turpis.



2010 © Centocor Ortho Biotech, Inc. This site is published by Centocor Ortho Biotech, Inc. which is solely responsible for its contents. It is intended for residents from the United States.



Notes

[Login](#) | [Registration](#) | [Patient Website](#)

[Print](#) | [e-mail a Colleague](#)

IMPORTANT SAFETY INFORMATION FOR REMICADE®

SERIOUS INFECTIONS
 Patients treated with REMICADE® (infliximab) are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue REMICADE® if a patient develops a serious infection or sepsis.

Reported infections include:

- Active tuberculosis (TB), including reactivation of latent TB. Patients frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent TB before and during treatment with REMICADE®.1,2 Treatment for latent infection should be initiated prior to treatment with REMICADE®.
- Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, and pneumocystosis. Patients may present with disseminated, rather than localized, disease. Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness.
- Bacterial, viral, and other infections due to opportunistic pathogens.

The risks and benefits of treatment with REMICADE® should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Closely monitor patients for the development of signs and symptoms of infection during and after treatment with REMICADE®, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.

In clinical trials, other serious infections observed in patients treated with REMICADE® included pneumonia, cellulitis, abscess, and skin ulceration.

MALIGNANCIES
 Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including REMICADE®. Approximately half of these cases were lymphomas, including Hodgkin's and non-Hodgkin's lymphoma. The other cases represented a variety of malignancies, including rare malignancies that are usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. The malignancies occurred after a median of 30 months after the first dose of therapy. Most of the patients were receiving concomitant immunosuppressants.

Postmarketing cases of hepatosplenic T-cell lymphoma, a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers, including REMICADE®. These cases have had a very aggressive disease course and have been fatal. All reported REMICADE® cases have occurred in patients with Crohn's disease or ulcerative colitis and the majority were in adolescent and young adult males. All of these patients had received treatment with azathioprine or 6-mercaptopurine concomitantly with REMICADE® at or prior to diagnosis. Carefully assess the risks and benefits of treatment with REMICADE®, especially in these patient types.

NOTE: The copy contained herein is for positioning and illustrative purposes only. For approved site copy please see the manuscript.